Arthneeti
All Q4 FY25 results →
KP

Koninklijke Philips N.V.

Q4 FY25Health Care Equipment and Supplies

Koninklijke Philips N.V. Q4 FY25 Results — Earnings Call Analysis

Q4 FY25 earnings call: what management said on revenue, margins and capex.

Price₹26
Market cap₹25.2K Cr
P/E23.2
Updated29 May 2026
Read4 min read

What the Q4 FY25 call signalled

2 of 4 strong

RevenueSlow growth
MarginMargins steady
CapexCapex planned
Order bookOrder book rising

The short version

- Philips expects continued strength and sustained momentum in North America with double-digit order growth, driven by both strong and expanding hospitals (pg. - Philips expects continued sales growth with a full-year comparable sales growth outlook of 1% to 3% for 2025.

From Koninklijke Philips N.V.'s Q4 FY25 earnings-call transcript · updated 29 May 2026.

Revenue & Sales Performance

Slow growth
  • Philips expects continued strength and sustained momentum in North America with double-digit order growth, driven by both strong and expanding hospitals (pg. 15).
  • Overall group comparable sales growth guidance is maintained at 1% to 3% for the full year 2025, with Q4 expected to show sequential improvement (pgs. 5, 13, 15).
  • Connected Care expected to grow within the 1%-3% sales range, Personal Health to grow slightly above mid-single-digit range, and Diagnosis & Treatment (D&T) to deliver slight year-over-year growth (pg. 5).
  • SKU reduction (Project Synchronized) and innovation are expected to continue supporting margin improvements and sales growth in 2026 and beyond (pg. 14).

2 more points from Koninklijke Philips N.V.'s call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Koninklijke Philips N.V. said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

Capex planned
  • Philips announced a EUR 150 million investment in the U.S. to expand production and strengthen cost efficiency and local supply continuity, particularly in Ultrasound and wider facilities (Page 7).
  • Further medium-term initiatives include supplier network enhancements and manufacturing location optimization to mitigate tariff impacts (Page 4 & 7).
  • Commitment to manufacturing footprint strengthening in the U.S. as part of reshoring efforts (Page 7).

2 more points from Koninklijke Philips N.V.'s call on capex

Create a free account to keep reading this call

Fundraising & Capital Structure

See what Koninklijke Philips N.V. said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

Order book rising
  • Q3 reported 8% order intake growth, predominantly driven by Connected Care (CC).
  • Strong order performance in Connected Care driven by hospital patient monitoring and partnerships.
  • Diagnostic & Treatment (D&T) orders were strong in Q2 and expected to further step up in Q4.
  • Order intake is expected to be positive in Q4, with a more even distribution between CC and D&T.
  • Enterprise Informatics (EI) order intake improved strongly in Q3, but conversion from orders to sales is slow due to long cycles.
  • Overall, the company maintains a strong order funnel and positive order momentum into Q4 and 2026.

2 more points from Koninklijke Philips N.V.'s call on order book

Create a free account to keep reading this call

Continue your research

Compare:vs Intuitive Surgical, Inc.vs Stryker Corporationvs Medtronic plc

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Koninklijke Philips N.V. and 15K+ more earnings calls,
for less than your morning chai

a day

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Koninklijke Philips N.V. Q4 FY25 results?

- Philips expects continued strength and sustained momentum in North America with double-digit order growth, driven by both strong and expanding hospitals (pg. - Philips expects continued sales growth with a full-year comparable sales growth outlook of 1% to 3% for 2025.

What is Koninklijke Philips N.V. share price analysis?

Koninklijke Philips N.V. currently shows a neutral. The stock trades at a P/E of 23.2 with a market cap of $25,162. Investors should review the full earnings analysis for detailed insights.

Is Koninklijke Philips N.V. planning capital expenditure?

- Philips announced a EUR 150 million investment in the U.S.

Keep Koninklijke Philips N.V. on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.